



**ContextVision**



ULTRA  
SOUND




GOPICE  
3D



X-RAY



MRI



IRV



MAMMO  
GRAPHY



CT

## CONTEXTVISION AB SECOND QUARTER 2017

### Q2 HIGHLIGHTS

- 24% sales increase over Q2 previous year
- Strong sales in all regions
- New product demo developed for AI based ultrasound segmentation
- New important collaboration with research team within Digital Pathology

### Q2 FINANCIAL DATA

- Sales of 22.7 MSEK (18.3)
- Operating result of 0.2 MSEK (-0.5) and operating margin of 0.7% (-3.0%)
- Research costs of 6.0 MSEK (4.4)
- Earnings per share of 0.0 (-0.1) SEK

## RECORD SALES WITH GROWTH IN ALL REGIONS

ANITA TOLLSTADIUS, THE COMPANY'S CEO COMMENTED:

*Sales in the second quarter reached as high as 22,7 MSEK, 24% higher than Q2 2016. Core business is strong and growing, thanks to continued investment into our product portfolio and commitment to our customers. Our cutting-edge research program allows us to further develop partnerships with our customers.*

Following a sales growth in all regions during the 2nd quarter, we reached 22,7 MSEK, a 24% increase over the second quarter last year and the highest sales ever during the second quarter. A particularly strong end-user demand was experienced in Asia, where sales increased by 32%. We continue to have high sales activities through our partners in Japan and Korea, and through our own organization in China.

The Chinese market has developed rapidly over the last few years and is still dynamic. Chinese manufacturers have increased their focus on new technology in order to deliver higher quality products. As they strive for this higher quality, our products become even more attractive. During the China International Medical Equipment Fair (CMEF) in Shanghai this past May, we had more visitors to our booth than ever before. The Chinese government continues to support domestic manufacturers and invest into the healthcare system. We are therefore very confident in the outlook for the Chinese market.

Sales in Europe increased by 6% and we had a very positive development in the U.S. market during the second quarter, with a 56% increase in license sales due to strong orders from existing customers.

We continue to make significant investments into research to support our commercial product offering and develop new innovative products and product features, all necessary investments to create a platform for future growth.

Ultrasound continues to be our key market, and thanks to the unique products we offer, we grew by more than 15% in the 2-D segment and by 27% within 3-D. In addition, we had strong growth from our XR products, with an increase of 61%. MRI also climbed 24% compared to the second quarter last year. Our products continue to be appreciated as we help our customers deliver the best possible image quality, which continues to be in high demand from healthcare providers.

Our research projects within our present business area, medical imaging, has focused on ultrasound. During the second quarter, we developed a demo for segmentation and identification of vessels in an ultrasound image. This new demo and our technically advanced prototype for

automated image optimization has allowed us to explore new product ideas and intensify our dialogue with key customers. This helps us share our vision and the resulting feedback helps us prioritize as we move forward. Although we are aware that the lead-times are long within the OEM business, we have generated much interest and feel encouraged about adding more value to our customers by developing new innovative products.

Our research project within digital pathology continues to make great progress: we entered the product development phase within prostate cancer and added to our team; the project is running at full speed. Some highlights from this quarter: we initiated a collaboration with a world-class research team in Uppsala. This team is part of Scilife, a recognized organization with world-leading competence in using highly specific antibodies and immunostaining to identify proteins in different tissues. The Uppsala team is linked to the pathology laboratory and expertise in pathology. Through this collaboration, we will create unique knowledge and thereby increase the quality of the input to the training of our deep learning algorithms. This way, we expect to develop products with unsurpassed performance. The methods will be designed to ensure extremely high accuracy in differentiating between types of cancer and grading the cancer. This will support pathologists in their daily work and help urologists make the right decision regarding treatment.

To make further progress within digital pathology, we have performed feasibility studies within other cancer forms this quarter and will continue to conduct research in these fields in close collaboration with leading pathologists.

During this quarter, we spent 6,0 MSEK on research and early product development. The level of capitalization is still low and thanks to our strong sales this quarter, we had slightly positive results. Following a negative cash flow (-3,1 MSEK) our cash position was still 37,8 MSEK, which secures further investments in both medical imaging and our new business area, digital pathology.

## SECOND QUARTER 2017

### NET SALES AND OPERATING PROFIT

#### NET SALES

- ContextVisions sales in the second quarter of 2017 amounted to 22.7 MSEK, which represents an increase of 24 % compared to the same quarter previous year, when sales ended at 18.3 MSEK.
- The currency exchange rates had an average effect on sales of 5.6% during the quarter, with the EUR and USD exchange rates representing most of the effect, while JPY changes had a smaller effect.

#### OPERATING PROFIT AND MARGIN

- ContextVisions operating result for the quarter was 0.2 MSEK (-0.5), with an operating margin of 0.7% (-3.0%).
- The cost for research within new areas (not capitalized) ended at 6.0 MSEK (4.4) during Q2. The increased research costs is a reflection of the ambitious drive towards entering a new and promising market.
- Capitalization is recorded as intangible fixed assets only when product development meets certain requirements. Capitalized costs for development of one product (total 0.4 MSEK) has been recorded during the quarter. This is in line with the level of capitalization compared to previous year, when the capitalization in the same quarter was 0.2 MSEK.
- The external costs for the quarter is higher in comparison to the same quarter previous year; mostly due to the ongoing research activities in the company.
- The increase in personnel costs for the quarter, compared to the same quarter last year, is explained by the slightly higher number of employees.

#### CASH-FLOW AND FINANCING

- Cash flow for the second quarter represented a negative change of -3.1 MSEK (0.6).
- Cash amounted to 37.8 MSEK (38.6) at period end.
- Equity at period end amounted to 58.8 MSEK (57.5) giving an equity ratio of 79.4% (77.1%).

### GOVERNMENT GRANT

- ContextVision was awarded a EU grant in 2015, together with its academic partner University of Applied Sciences an Arts Western Switzerland (HES-SO).
- The company's total part of the grant is TEUR 404, and it will be paid out during a three-year period.
- The first part of the grant (0.6 MSEK) was received in Q4 2015.
- The second part of the grant (1.3 MSEK) was received in Q4 2016, and was recorded as a cost decrease.
- The grant for 2017 is expected to be received in Q4, and will then be recorded as a cost decrease. The grant has therefore not been recorded in the P&L statement and has not affected the results for Q2.

### EMPLOYEES AND MANAGEMENT

- At period end the company had 42 (41) employees of which 22 (20) are dedicated to research and development. 2 employees are located in the USA and 1 in China.

### CONTEXTVISION GROUP

- The group consists of ContextVision AB (publ), company registration number 556377-8900 as the parent company, and ContextVision Inc Corp registration number 36-4333625 State of Illinois, USA, as the wholly owned subsidiary.
- Operations in the group are conducted primarily in the parent company and consist of research and development, sales, marketing and administrative functions.

### RISKS & UNCERTAINTIES

- ContextVision's major risk factors include business risks connected to the general global financial situation, to the level of healthcare investment on different markets, currency exchange risks, the company's ability to recruit and keep qualified employees and the effect of political decisions.
- The company's risk factors are described in the annual report 2016. The risks and uncertainties have not changed significantly since then.
- This quarterly report provides a fair and true overview of the company's and the Group's activities, position and results, and describes the risks and uncertainties of significance faced by ContextVision and by the companies in the Group.

## SUBSEQUENT EVENTS

- No significant events have occurred during the period between year-end and date of issuance of this report.

The Board of Directors of ContextVision AB  
Stockholm 2017-08-16

*This report has not been reviewed by the company's auditors.*

## PRESENTATION AND REPORTING DATES

This quarterly report will be published on the company's website on the 17<sup>th</sup> of August, 2017.

There will be a video presentation released on the 18<sup>th</sup> of August, at 09.00 CET.

Please follow the link:  
<http://webtv.nu/contextvisionq22017>

Please visit [www.contextvision.com](http://www.contextvision.com) for further information, or use [shareholderinfo@contextvision.se](mailto:shareholderinfo@contextvision.se) to send a question directly to management.

### REPORTING DATES

Q4 and annual result 2016	February 23, 2017
Annual report available	April 6, 2017
Q1 result 2017	April 27, 2017
Annual General Meeting	May 10, 2017
Q2 result 2017	August 17, 2017
Q3 result 2017	October 26, 2017
Q4 and 12 months 2017	February 22, 2018

### FOR MORE INFORMATION PLEASE CONTACT:

Anita Tollstadius, CEO  
Phone +46 (0)8 750 35 50

## CONTEXTVISION FAST FACTS

- ContextVision is a spin-off from the Image Processing Laboratory at Linköping University, Sweden. The corporate identity was established in 1983 with the first OEM agreement in radiology in 1987. ContextVision is traded on the Oslo Stock Exchange since 1997.
- ContextVision has a specialist competence within medical image processing and artificial intelligence technologies.
- A world leader in image enhancement using proprietary technology based on GOP.
- ContextVision has entered into a new progressive phase to become a leader within new technologies, such as deep learning.
- The Company is running a research program to take a leading position on the new, fast growing digital pathology market.

### THE COMPANY OFFERS:

- 30 years of successful experience in OEM business.
- Unprecedented image enhancement for ultrasound, X-Ray, MRI, CT, mammography and iRV.
- Long standing corporate commitment to R&D that ensures timely and rewarding upgrade paths.
- Strong customer relationships to ensure their success.
- Expert training in image processing for our customers.
- Compatibility across different image formats and major computer platforms.
- ContextVision's technology enables the company's customers to provide superior digital imaging solutions for hospitals and clinicians. Such solutions promise more rapid and accurate diagnoses, reduced operator eye fatigue, and ultimately, a greater return-on-investment for medical imaging users.

**CONSOLIDATED INCOME STATEMENT (SEK 1000)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Net sales	22 744	18 300	40 005	36 721	81 917
<b>Total revenues</b>	<b>22 744</b>	<b>18 300</b>	<b>40 005</b>	<b>36 721</b>	<b>81 917</b>
Goods for resale	-522	-423	-934	-921	-2 448
Other external costs	-7 751	-5 044	-14 528	-9 657	-23 369
Personnel costs	-12 950	-12 266	-25 070	-23 102	-45 507
Depreciation assets	-1 359	-1 113	-2 702	-2 166	-4 824
<b>Operating results</b>	<b>161</b>	<b>-546</b>	<b>-3 229</b>	<b>875</b>	<b>5 769</b>
Interest income	1	0	0	0	-
Interest cost	-10	-5	-10	-4	-2
<b>Results after financial items</b>	<b>152</b>	<b>-551</b>	<b>-3 239</b>	<b>871</b>	<b>5 767</b>
Tax	-66	81	675	-225	-1 514
<b>Net results</b>	<b>86</b>	<b>-471</b>	<b>-2 564</b>	<b>646</b>	<b>4 253</b>
Earnings per share after tax (SEK)	0,01	-0,06	-0,33	0,08	0,55

**CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Effect of currency hedging	-32	-248	18	-193	-24
Translation difference	-82	67	-110	28	161
<b>Total other comprehensive income</b>	<b>-114</b>	<b>-181</b>	<b>-92</b>	<b>-165</b>	<b>137</b>
Net result for the period	86	-471	-2 564	646	4 253
<b>Total comprehensive income for the period</b>	<b>-28</b>	<b>-652</b>	<b>-2 656</b>	<b>481</b>	<b>4 390</b>

**FINANCIAL HIGHLIGHTS**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Earnings per share after tax (SEK) before/after dilution	0,01	-0,06	-0,33	0,08	0,55
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	0,7	-3,0	-8,1	2,4	7,0
Solidity (per cent)	77,9	77,1	77,9	77,1	77,5

**DEFINITIONS**

*Operating margin: Operating income excluding non-recurring items as a percentage of net sales.*

*Profit margin: Result after financial items as a percentage of net sales.*

*Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity.*

*Solidity (Equity ratio): Equity as a percentage of total assets.*

**SALES BY REGION (MSEK)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Asia	11,1	8,4	19,6	18,0	42,6
Europe	7,7	7,3	14,5	13,0	28,6
USA	3,9	2,5	5,9	5,7	10,7
<b>Total</b>	<b>22,7</b>	<b>18,3</b>	<b>40,0</b>	<b>36,7</b>	<b>81,9</b>

**SALES BY PRODUCT (MSEK)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
XR	3,7	2,3	6,1	4,7	10,0
US 2D	12,0	10,4	22,3	21,0	47,9
US 3D	3,8	3,0	6,3	5,0	11,4
MR	2,6	2,1	3,7	5,2	10,5
Others (iRV, CT, Mammo)	0,6	0,5	1,6	0,8	2,1
<b>Total</b>	<b>22,7</b>	<b>18,3</b>	<b>40,0</b>	<b>36,7</b>	<b>81,9</b>

**CONSOLIDATED BALANCE SHEET (SEK 1000)**

	Q2, 2017	Q2 2016			FULL YEAR 2016
Intangible fixed assets	12 707	16 804			14 628
Tangible assets	584	583			527
Other financial assets	328	254			323
Inventories	654	586			294
Current receivables	23 353	17 787			20 616
Cash and bank	37 805	38 582			42 910
<b>Total assets</b>	<b>75 431</b>	<b>74 597</b>			<b>79 299</b>
Equity	58 770	57 517			61 426
Deferred taxes	1 521	1 114			1 508
Current liabilities	15 140	15 966			16 365
<b>Total equity and liabilities</b>	<b>75 431</b>	<b>74 597</b>			<b>79 299</b>

**CHANGE IN EQUITY (SEK 1000)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Opening balance	58 797	58 169	61 426	57 036	57 036
Total comprehensive income for the period	-28	-652	-2 656	481	4 390
<b>Closing balance</b>	<b>58 770</b>	<b>57 517</b>	<b>58 770</b>	<b>57 517</b>	<b>61 426</b>

**CONSOLIDATED STATEMENT OF CASH FLOWS (SEK 1000)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Result after financial items	152	-551	-3 239	871	5 767
Depreciation and write-down of assets	1 491	1 113	2 921	2 166	6 164
Unrealized gain/loss on current investments	-32	-248	18	-193	-24
Income tax paid	-3 576	-1 520	-3 776	-1 983	-1 399
<b>Cash flow from operating activities</b>	<b>-1 965</b>	<b>-1 206</b>	<b>-4 076</b>	<b>861</b>	<b>10 508</b>
before change in working capital					
<b>Change in working capital</b>					
Increase (-)/decrease (+) inventories	161	-330	-360	-190	102
Increase (-)/decrease (+) current receivables	-2 509	-1 671	593	2 203	-3 448
Increase (+)/decrease (-) liabilities	-1 591	4 001	-276	1 686	2 365
<b>Cash flow from operating activities</b>	<b>-2 722</b>	<b>794</b>	<b>-4 119</b>	<b>4 560</b>	<b>9 527</b>
<b>Investing activities</b>					
Investments in intangible assets	-386	-239	-815	-1 459	-1 976
Investments in tangible assets	-29	-	-167	-161	-215
Other financial assets	-5	-	-5	-	-69
<b>Cash flow from investing activities</b>	<b>-420</b>	<b>-239</b>	<b>-987</b>	<b>-1 620</b>	<b>-2 260</b>
Financing activities					
Cash flow from financing activities	0	0	0	0	0
<b>Cash flow for the period</b>	<b>-3 142</b>	<b>555</b>	<b>-5 106</b>	<b>2 940</b>	<b>7 266</b>
Change of liquid assets					
Liquid assets at beginning of period	40 946	38 028	42 910	35 644	35 644
<b>Liquid assets at period end</b>	<b>37 805</b>	<b>38 582</b>	<b>37 805</b>	<b>38 582</b>	<b>42 910</b>



**PARENT COMPANY INCOME STATEMENT (SEK 1000)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Net sales	22 744	18 300	40 005	36 721	81 917
<b>Total revenues</b>	<b>22 744</b>	<b>18 300</b>	<b>40 005</b>	<b>36 721</b>	<b>81 917</b>
Goods for resale	-522	-423	-934	-921	-2 448
Other external costs	-8 780	-5 880	-16 452	-11 287	-26 715
Personnel costs	-11 982	-11 482	-23 267	-21 567	-42 374
Depreciation assets	-1 359	-1 113	-2 702	-2 166	-4 824
<b>Operating results</b>	<b>100</b>	<b>-598</b>	<b>-3 350</b>	<b>780</b>	<b>5 556</b>
Interest income	1	-	-	-	-
Interest cost	-10	-5	-10	-3	-2
Dividends from group company	-	-	-	-	275
<b>Results after financial items</b>	<b>91</b>	<b>-603</b>	<b>-3 360</b>	<b>776</b>	<b>5 829</b>
Provision for tax allocation reserve	-	-	-	-	-1 500
Tax	-45	93	669	-223	-985
<b>Net results</b>	<b>47</b>	<b>-510</b>	<b>-2 691</b>	<b>553</b>	<b>3 344</b>
Earnings per share after tax (SEK)	0,01	-0,07	-0,35	0,07	0,43

**PARENT COMPANY STATEMENT OF COMPREHENSIVE INCOME (SEK 1000)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Effect of currency hedging	-31	-248	18	-192	-24
<b>Total other comprehensive income</b>	<b>-31</b>	<b>-248</b>	<b>18</b>	<b>-192</b>	<b>-24</b>
Net result for the period	47	-510	-2 691	553	3 344
<b>Total comprehensive income for the period</b>	<b>16</b>	<b>-758</b>	<b>-2 673</b>	<b>361</b>	<b>3 320</b>

**FINANCIAL HIGHLIGHTS**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Earnings per share after tax (SEK) before/after dilution	0,01	-0,07	-0,35	0,07	0,43
Average number of shares	7 736 750	7 736 750	7 736 750	7 736 750	7 736 750
Operating margin (per cent)	0,4	-3,3	-8,4	2,1	6,8
Solidity (per cent)	69,4	69,7	69,4	69,7	69,4

**DEFINITIONS**

*Operating margin: Operating income excluding non-recurring items as a percentage of net sales.*

*Profit margin: Result after financial items as a percentage of net sales.*

*Earnings per share after tax (Return on equity): Net result for the period as a percentage of the average equity.*

*Solidity (Equity ratio): Equity as a percentage of total assets.*

**SALES BY REGION (MSEK)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Asia	11,1	8,4	19,6	18,0	42,6
Europe	7,7	7,3	14,5	13,0	28,6
USA	3,9	2,5	5,9	5,7	10,7
<b>Total</b>	<b>22,7</b>	<b>18,3</b>	<b>40,0</b>	<b>36,7</b>	<b>81,9</b>

**SALES BY PRODUCT (MSEK)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
XR	3,7	2,3	6,1	4,7	10,0
US 2D	12,0	10,4	22,3	21,0	47,9
US 3D	3,8	3,0	6,3	5,0	11,4
MR	2,6	2,1	3,7	5,2	10,5
Others (iRV, CT, Mammo)	0,6	0,5	1,6	0,8	2,1
<b>Total</b>	<b>22,7</b>	<b>18,3</b>	<b>40,0</b>	<b>36,7</b>	<b>81,9</b>

**PARENT COMPANY BALANCE SHEET (SEK 1000)**

	MAR 31 <sup>ST</sup> 2017	MAR 31 <sup>ST</sup> 2016		FULL YEAR 2016
Intangible fixed assets	12 707	16 805		14 628
Tangible assets	584	583		527
Other financial assets	545	471		540
Inventories	654	586		294
Current receivables	23 312	17 749		20 571
Cash and bank	37 448	38 230		42 501
<b>Total assets</b>	<b>75 250</b>	<b>74 424</b>		<b>79 061</b>
Equity	52 190	51 903		54 862
Untaxed reserves	6 786	5 209		6 773
Current liabilities	16 274	17 312		17 426
<b>Total equity and liabilities</b>	<b>75 250</b>	<b>74 424</b>		<b>79 061</b>

**CHANGE IN EQUITY (SEK 1000)**

	Q2 2017	Q2 2016	SIX MONTHS 2017	SIX MONTHS 2016	FULL YEAR 2016
Opening balance	52 174	52 661	54 862	51 542	51 542
Total comprehensive income for the period	16	-758	-2 673	361	3 320
<b>Closing balance</b>	<b>52 190</b>	<b>51 903</b>	<b>52 190</b>	<b>51 903</b>	<b>54 862</b>

**BASIS OF PREPARATION**

The interim condensed consolidated financial statements for the 2:nd quarter ended June 30, 2017 have been prepared in accordance with IAS 34 Interim Financial Reporting and recommendation RFR 1 of the Swedish Financial Reporting Board (RFR), and with regards to the Parent Company, RFR 2. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as of December 31, 2016. There has been no changes in the accounting principles or methods for calculation during the period.

## GLOSSARY

### **ARTIFICIAL INTELLIGENCE (AI)**

Artificial Intelligence is the intelligence exhibited by machines or software.

### **DEEP LEARNING**

Deep learning is the latest very powerful technology within machine learning; machine learning with deep neural networks

### **DIGITAL PATHOLOGY**

Digital pathology refers to the digital images of histopathology samples. The digitalization is achieved by scanning the prepared samples.

### **GOP® (GENERAL OPERATOR PROCESSOR)**

ContextVision's methodology and technology base for image analysis and image enhancement, detecting structures in an image and relating them to their wider context in order to increase visualization accuracy.

### **GOPICE® (IMAGE CUBICLE ENHANCEMENT)**

ContextVision's real-time 3D volumetric image enhancement product, for OEM embedded software.

### **GOPVIEW® / PLUSVIEW®**

The family names for ContextVision's 2D product lines of OEM-embedded software.

### **IMAGE ANALYSIS**

Processing a digital image in order to describe/classify its contents or to extract quantitative measurements.

### **IMAGE PROCESSING**

A generic term used to describe the computation of digital images, typically to enhance or analyze them.

### **IMAGE ENHANCEMENT**

To improve the visual quality of a digital image by increasing the visibility of relevant structures, as in edge/contrast enhancement and the suppression of noise or artifacts.

### **MACHINE LEARNING**

Machine learning is the study of computer algorithms that improve automatically through experience

### **MAMMOGRAPHY**

An X-ray method used to examine the human breast.

### **MODALITY**

A device that generates internal images of the body, such as X-ray, ultrasound, magnetic resonance imaging, and computed tomography.

### **MRI (MAGNETIC RESONANCE IMAGING)**

A non-invasive procedure, generated by variations in strong magnetic fields, that produces a two-dimensional view of an internal organ or structure, especially the brain and spinal cord.

### **OEM**

The acronym for Original Equipment Manufacturer.

### **REALICE™**

REALiCE is a volume enhancement and rendering product package for 3D and 4D fetal volume visualization.

### **US (ULTRASOUND)**

A procedure in which high-energy sound waves are bounced off internal tissues or organs to create echoes. The echo patterns are displayed on the screen of an ultrasound machine, forming a picture of body tissues called a sonogram.

### **XR (X-RAY)**

A diagnostic device in which radiation is used to create images for examination of soft and hard tissue, such as muscle and bone.



ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision has decided to take a lead position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing heavily in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D Ultrasound, MRI, X-Ray and Mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV.



**FOR MORE INFORMATION, PLEASE VISIT [WWW.CONTEXTVISION.COM](http://WWW.CONTEXTVISION.COM)**